Literature DB >> 22815152

Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Leslie Wagner1, Anita Verma, Bruce D Meade, Karine Reiter, David L Narum, Rebecca A Brady, Stephen F Little, Drusilla L Burns.   

Abstract

New anthrax vaccines currently under development are based on recombinant protective antigen (rPA) and formulated with aluminum adjuvant. Because long-term stability is a desired characteristic of these vaccines, an understanding of the effects of adsorption to aluminum adjuvants on the structure of rPA is important. Using both biophysical and immunological techniques, we compared the structure and immunogenicity of freshly prepared rPA-Alhydrogel formulations to that of formulations stored for 3 weeks at either room temperature or 37°C in order to assess the changes in rPA structure that might occur upon long-term storage on aluminum adjuvant. Intrinsic fluorescence emission spectra of tryptophan residues indicated that some tertiary structure alterations of rPA occurred during storage on Alhydrogel. Using anti-PA monoclonal antibodies to probe specific regions of the adsorbed rPA molecule, we found that two monoclonal antibodies that recognize epitopes located in domain 1 of PA exhibited greater reactivity to the stored formulations than to freshly prepared formulations. Immunogenicity of rPA-Alhydrogel formulations in mice was assessed by measuring the induction of toxin-neutralizing antibodies, as well as antibodies reactive to 12-mer peptides spanning the length of PA. Mice immunized with freshly prepared formulations developed significantly higher toxin-neutralizing antibody titers than mice immunized with the stored preparations. In contrast, sera from mice immunized with stored preparations exhibited increased reactivity to nine 12-mer peptides corresponding to sequences located throughout the rPA molecule. These results demonstrate that storage of rPA-Alhydrogel formulations can lead to structural alteration of the protein and loss of the ability to elicit toxin-neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815152      PMCID: PMC3428410          DOI: 10.1128/CVI.00174-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen.

Authors:  J L Elliott; J Mogridge; R J Collier
Journal:  Biochemistry       Date:  2000-06-06       Impact factor: 3.162

2.  The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.

Authors:  Jeremy Mogridge; Kristina Cunningham; D Borden Lacy; Michael Mourez; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

3.  Exchange characteristics of calcium ions bound to anthrax protective antigen.

Authors:  Samantha Gao-Sheridan; Sen Zhang; R John Collier
Journal:  Biochem Biophys Res Commun       Date:  2003-01-03       Impact factor: 3.575

4.  Acid induced unfolding of anthrax protective antigen.

Authors:  Pradeep K Gupta; Raj K Kurupati; Harish Chandra; Reetika Gaur; Vibha Tandon; Yogendra Singh; Kapil Maithal
Journal:  Biochem Biophys Res Commun       Date:  2003-11-07       Impact factor: 3.575

5.  Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Authors:  Andrei Soliakov; Ian F Kelly; Jeremy H Lakey; Allan Watkinson
Journal:  Eur J Pharm Biopharm       Date:  2011-09-22       Impact factor: 5.571

6.  In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Authors:  M L Pitt; S F Little; B E Ivins; P Fellows; J Barth; J Hewetson; P Gibbs; M Dertzbaugh; A M Friedlander
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

7.  Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen.

Authors:  Arunee Wittayanukulluk; Dongping Jiang; Fred E Regnier; Stanley L Hem
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

8.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

Review 9.  Anthrax toxin.

Authors:  R John Collier; John A T Young
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

10.  Conformational fluctuations in anthrax protective antigen: a possible role of calcium in the folding pathway of the protein.

Authors:  Pradeep K Gupta; Harish Chandra; Reetika Gaur; Raj K Kurupati; Shantanu Chowdhury; Vibha Tandon; Yogendra Singh; Kapil Maithal
Journal:  FEBS Lett       Date:  2003-11-20       Impact factor: 4.124

View more
  22 in total

1.  Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.

Authors:  Anita Verma; Miriam M Ngundi; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

2.  Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.

Authors:  Joanne M O'Hara; Robert N Brey; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2013-03-20

3.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

Review 4.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

5.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

6.  Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen.

Authors:  Ekaterina M Ryabchevskaya; Ekaterina A Evtushenko; Dmitry L Granovskiy; Peter A Ivanov; Joseph G Atabekov; Olga A Kondakova; Nikolai A Nikitin; Olga V Karpova
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

7.  Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen.

Authors:  Anita Verma; Beth McNichol; Rocío I Domínguez-Castillo; Juan C Amador-Molina; Juan L Arciniega; Karine Reiter; Bruce D Meade; Miriam M Ngundi; Scott Stibitz; Drusilla L Burns
Journal:  Infect Immun       Date:  2012-10-31       Impact factor: 3.441

8.  Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice.

Authors:  Juergen Zlatkovic; Georgios Tsouchnikas; Johanna Jarmer; Christian Koessl; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

9.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

10.  A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.

Authors:  Manish Manish; Amit Rahi; Manpreet Kaur; Rakesh Bhatnagar; Samer Singh
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.